jinnianhui金年会|金字招牌诚信至上

jinnianhui金年会生物

jinnianhui金年会生物

In China, For Global

An innovative and globally competitive

biopharmaceutical company with a whole-industry-chain layout.

In China, For Global

An innovative and globally competitive

biopharmaceutical company with a whole-industry-chain layout.

Original Innovation, Science Oriented

Globally-integrated R&D process

Technology system encompassing the entire lifecycle of antibodies

Innovation-driven Biopharma

China’s leading innovative biopharmaceutical company

Established in December, 2012

Therapeutic Area

  • Oncology

    Toripalimab (PD-1), Tifcemalimab (BTLA)…

  • Autoimmune

    Adalimumab (TNF-α), JS005 (IL-17A), UBP1213sc (BLyS)

  • Metabolic

    Ongericimab (PCSK9), JS103 (Uricase), JS401 (ANGPTL3)…

  • Neurological

    JS010 (CGRP)

  • Infectious

    Etesevimab (S protein), Deuremidevir Hydrobromide (RdRp)…

Therapeutic Area

  • Oncology
  • Autoimmune
  • Metabolic
  • Neurological
  • Infectious
Learn more

Our Milestones

News Center

  • Nov 16, 2024

    Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab

    >The UK MHRA has approved toripalimab for the treatment of NPC and ESCC

    View details
  • Oct 12, 2024

    Junshi Biosciences Announces Ongericimab’s NDA Approval in China

    >The NMPA approved the NDA for ongericimab (PCSK9) for the treatment of primary hypercholesterolemia and mixed dyslipidemia (in combination with statins)

    View details
  • Sep 25, 2024

    Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab

    >The European Commission has approved toripalimab for the 1st-line treatment of advanced NPC and ESCC

    View details
  • Apr 7, 2024

    Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer

    >The NMPA has approved the supplemental new drug application for toripalimab in combination with axitinib for the first-line treatment of patients with medium to high risk unresectable or metastatic renal cell carcinoma

    View details
Join us

用世界一流、值得信赖的创新药普惠患者

View details
友情链接: